- On Friday, Repligen Corporation (NASDAQ:RGEN) said in a regulatory filing that it has extended a long-term supply agreement with Cytiva Sweden AB through 2025.
- The deal covered the contract manufacturing of Cytiva ligands at Repligen’s manufacturing plants in Waltham, MA, and Lund, Sweden.
Repligen extends contract manufacturing agreement with Cytiva though 2025
Recommended For You
About RGEN Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| RGEN | - | - |
| Repligen Corporation | ||